Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1295-1302

  Schneider, Abraham ^a,b   Younis, Rania H ^a   Gutkind, J Silvio ^c  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN DERIVATIVE; PROTEIN S6; REGULATED IN DEVELOPMENT AND DNA DAMAGE 1; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DEREGULATION; ENERGY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STRESS; UPREGULATION;

EID: 55849109650     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08586     Document Type: Article

References (40)

1. Gatenby RA and Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899.
2. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
3. Pouyssegur J, Dayan F, and Mazure NM (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443.
4. Bacon AL and Harris AL (2004). Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 36, 530-539.
5. Isa AY, Ward TH, West CM, Slevin NJ, and Homer JJ (2006). Hypoxia in head and neck cancer. Br J Radiol 79, 791-798.
6. Janssen HL, Haustermans KM, Balm AJ, and Begg AC (2005). Hypoxia in head and neck cancer: how much, how important? Head Neck 27, 622-638.
7. Sabatini DM (2006). mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6, 729-734.
8. Reiling JH and Sabatini DM (2006). Stress and mTORture signaling. Oncogene 25, 6373-6383.
9. Arsham AM, Howell JJ, and Simon MC (2003). A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278, 29655-29660.
10. Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, et al. (2006). Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 25, 1114-1125.
11. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, and Simon MC (2006). Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21, 521-531.
12. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, and Gutkind JS (2005). Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65, 9953-9961.
13. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, and Gutkind JS (2004). Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10, 4029-4037.
14. Hebert C, Norris K, Parashar P, Ord RA, Nikitakis NG, and Sauk JJ (2006). Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer 5, 3.
15. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A, Raimondi AR, Jufe R, Itoiz M, Gao Y, et al. (2007). Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13, 4964-4973.
16. Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, and Glass J (2004). Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10, 5820-5827.
17. Reiling JH and Hafen E (2004). The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 18, 2879-2892.
18. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, and Kaelin WG Jr (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18, 2893-2904.
19. Sofer A, Lei K, Johannessen CM, and Ellisen LW (2005). Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 25, 5834-5845.
20. Corradetti MN, Inoki K, and Guan KL (2005). The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280, 9769-9772.
21. Inoki K, Zhu T, and Guan KL (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590.
22. Alessi DR, Sakamoto K, and Bayascas JR (2006). LKB1-dependent signaling pathways. Annu Rev Biochem 75, 137-163.
23. Jeon GA, Lee JS, Patel V, Gutkind JS, Thorgeirsson SS, Kim EC, Chu IS, Amornphimoltham P, and Park MH (2004). Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 112, 249-258.
24. DeYoung MP, Horak P, Sofer A, Sgroi D, and Ellisen LW (2008). Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22, 239-251.
25. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, et al. (2002). Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22, 2283-2293.
26. Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, and Kaufmann J (2005). REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 24, 1138-1149.
27. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, and Thompson CB (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7, 11-20.
28. Kahn BB, Alquier T, Carling D, and Hardie DG (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1, 15-25.
29. Stein SC, Woods A, Jones NA, Davison MD, and Carling D (2000). The regulation of AMP-activated protein kinase by phosphorylation. Biochem J 345 Pt 3, 437-443.
30. Forastiere A, Koch W, Trotti A, and Sidransky D (2001). Head and neck cancer. N Engl J Med 345, 1890-1900.
31. Le Tourneau C, Faivre S, and Siu LL (2007). Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer 43, 2457-2466.
32. Bussink J, van der Kogel AJ, and Kaanders JH (2008). Activation of the PI3-K/ AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9, 288-296.
33. Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE, and Lingen MW (2008). Tissue microarray - a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med 37, 166-176.
34. Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, and Sanchez-Cespedes M (2006). Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12, 710-717.
35. Kalyankrishna S and Grandis JR (2006). Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24, 2666-2672.
36. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et al. (2006). Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12, 5064-5073.
37. Abraham RT (2005). TOR signaling: an odyssey from cellular stress to the cell growth machinery. Curr Biol 15, R139-R141.
38. Hoogsteen IJ, Marres HA, Bussink J, van der Kogel AJ, and Kaanders JH (2007). Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29, 591-604.
39. Vaupel P and Mayer A (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26, 225-239.
40. Li Y, Wang Y, Kim E, Beemiller P, Wang CY, Swanson J, You M, and Guan KL (2007). Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 282, 35803-35813.